eflornithine has been researched along with Cancer of Prostate in 49 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "alpha-Difluoromethylornithine (DFMO) and methylglyoxal-bis-guanylhydrazone (MGBG), when administered simultaneously, inhibited growth and were highly toxic to the Dunning R 3327-G hormone-resistant prostatic adenocarcinoma transplanted into Copenhagen rats." | 3.67 | Antigrowth effect of polyamine biosynthesis inhibitors on the Dunning R 3327-G prostatic tumor. ( Herr, HW; Kleinert, EL, 1984) |
| "The potential of this compound for prostate cancer or hyperplasia should be further studied." | 2.73 | The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. ( Ahlering, TE; Anton-Culver, H; Fujikawa-Brooks, S; Gerner, EW; Lieberman, R; McLaren, CE; Meyskens, FL; Nagle, R; Simoneau, AR; Yerushalmi, H; Ziogas, A, 2008) |
| " The dosage of PXM 10 mg q." | 2.69 | Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine. ( Blair, IA; Carbone, PP; Douglas, JA; Larson, PO; Pomplun, M; Tutsch, KD; Verma, AK, 1998) |
| " DFMO has shown a dose-response effect in tumor inhibition in mice." | 2.67 | Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. ( Carbone, PP; Carey, P; Gilmore, D; Love, RR; Pomplun, M; Tutsch, KD; Verma, AK; Wilding, G, 1993) |
| "In 2010, in France, 8,790 men died from prostate cancer despite a low and decreasing mortality rate." | 2.49 | [Pharmaco and diet based prostate cancer prevention]. ( Azzouzi, AR; Cancel-Tassin, G; Cussenot, O; Eisinger, F; Gravis, G; Rossi, D, 2013) |
| "Primary prevention of prostate cancer is a relatively new concept." | 2.39 | Chemoprevention of prostate cancer. ( Brawley, OW; Thompson, IM, 1994) |
| "Putrescine is a small molecule that may prove difficult for use for synthesizing stable toxin derivatives that can take advantage of the targeting potential of the polyamine transporter." | 2.38 | Prostatic polyamines and polyamine targeting as a new approach to therapy of prostatic cancer. ( Heston, WD, 1991) |
| " However, a dose-response reduction in invasive carcinoma growth was observed for both DFMO, an inhibitor of ornithine decarboxylase, and DHEA, the primary steroid precursor to both androgens and estrogens in primates." | 1.31 | 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. ( Anver, MR; Green, JE; Kelloff, G; Lubet, R; Moon, RC; Shibata, E; Shibata, MA, 2001) |
| " These data suggest that differentiation agents may provide additional antineoplastic benefits when administered in combination with selected chemotherapeutic agents in the management of prostatic cancer." | 1.28 | Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma. ( Carvalho, L; Foulkes, K; Mickey, DD, 1989) |
| "Putrescine is a potential scanning agent for metastases of prostatic carcinoma." | 1.27 | alpha-Difluoromethylornithine enhancement of 14C-putrescine uptake by an androgen-dependent prostatic tumor. ( Heston, WD; Kadmon, D, 1986) |
| "Putrescine was able to block the cytotoxic effect of AZP." | 1.27 | Cytotoxic activity of a polyamine analogue, monoaziridinylputrescine, against the PC-3 human prostatic carcinoma cell line. ( Covey, DF; Heston, WD; Pliner, L; Russo, P; Yang, CR, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (44.90) | 18.7374 |
| 1990's | 14 (28.57) | 18.2507 |
| 2000's | 11 (22.45) | 29.6817 |
| 2010's | 2 (4.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eisinger, F | 1 |
| Cancel-Tassin, G | 1 |
| Azzouzi, AR | 1 |
| Gravis, G | 1 |
| Rossi, D | 1 |
| Cussenot, O | 1 |
| Meyskens, FL | 3 |
| Simoneau, AR | 3 |
| Gerner, EW | 3 |
| Pasanen, T | 1 |
| Karppinen, A | 1 |
| Alhonen, L | 1 |
| Jänne, J | 1 |
| Wahlfors, J | 1 |
| Kee, K | 1 |
| Vujcic, S | 1 |
| Merali, S | 1 |
| Diegelman, P | 1 |
| Kisiel, N | 1 |
| Powell, CT | 1 |
| Kramer, DL | 1 |
| Porter, CW | 1 |
| Christov, KT | 1 |
| Moon, RC | 2 |
| Lantvit, DD | 1 |
| Boone, CW | 1 |
| Kelloff, GJ | 1 |
| Steele, VE | 1 |
| Lubet, RA | 1 |
| Pezzuto, JM | 1 |
| Ranger-Moore, J | 1 |
| Alberts, DS | 1 |
| Montironi, R | 2 |
| Garcia, F | 1 |
| Davis, J | 1 |
| Frank, D | 1 |
| Brewer, M | 1 |
| Mariuzzi, GM | 1 |
| Bartels, HG | 1 |
| Bartels, PH | 2 |
| Nagle, R | 1 |
| Ziogas, A | 1 |
| Fujikawa-Brooks, S | 1 |
| Yerushalmi, H | 1 |
| Ahlering, TE | 1 |
| Lieberman, R | 1 |
| McLaren, CE | 2 |
| Anton-Culver, H | 1 |
| Dunzendorfer, U | 4 |
| Relyea, NM | 2 |
| Kleinert, E | 1 |
| Balis, ME | 2 |
| Whitmore, WF | 3 |
| Herr, HW | 3 |
| Kleinert, EL | 2 |
| Heston, WD | 7 |
| Kadmon, D | 5 |
| Covey, DF | 3 |
| Fair, WR | 4 |
| Releyea, N | 1 |
| Fogh, J | 1 |
| Lazan, DW | 2 |
| Thompson, IM | 3 |
| Coltman, CA | 1 |
| Brawley, OW | 3 |
| Ryan, A | 1 |
| Cipolla, B | 3 |
| Guillé, F | 3 |
| Moulinoux, JP | 3 |
| Quemener, V | 3 |
| Staerman, F | 1 |
| Corbel, L | 1 |
| Lobel, B | 2 |
| Love, RR | 2 |
| Carbone, PP | 2 |
| Verma, AK | 3 |
| Gilmore, D | 1 |
| Carey, P | 1 |
| Tutsch, KD | 3 |
| Pomplun, M | 3 |
| Wilding, G | 3 |
| Blount, LV | 1 |
| Cooke, DB | 2 |
| Blanchard, Y | 1 |
| Chamaillard, L | 1 |
| Havouis, R | 2 |
| Douglas, JA | 1 |
| Larson, PO | 1 |
| Blair, IA | 1 |
| Messing, EM | 1 |
| Douglas, J | 1 |
| Simsiman, R | 1 |
| Mazzucchelli, R | 1 |
| Marshall, JR | 1 |
| Gupta, S | 1 |
| Ahmad, N | 1 |
| Marengo, SR | 1 |
| MacLennan, GT | 1 |
| Greenberg, NM | 1 |
| Mukhtar, H | 1 |
| Weeks, RS | 1 |
| Vanderwerf, SM | 1 |
| Carlson, CL | 1 |
| Burns, MR | 1 |
| O'Day, CL | 1 |
| Cai, F | 1 |
| Devens, BH | 1 |
| Webb, HK | 1 |
| Phung, M | 1 |
| Walczak, J | 1 |
| Wood, H | 1 |
| Williams, T | 1 |
| Bishop, CW | 1 |
| Carducci, M | 1 |
| Green, JE | 1 |
| Shibata, MA | 1 |
| Shibata, E | 1 |
| Anver, MR | 1 |
| Kelloff, G | 1 |
| Lubet, R | 1 |
| Donald, CD | 1 |
| Cooper, CR | 1 |
| Harris-Hooker, S | 1 |
| Emmett, N | 1 |
| Scanlon, M | 1 |
| Martin, C | 1 |
| Seiler, N | 1 |
| Johnson, M | 1 |
| Shaw, M | 2 |
| Rubenstein, M | 2 |
| Guinan, P | 2 |
| Knöner, M | 1 |
| Hwang, DR | 1 |
| Lang, LX | 1 |
| Mathias, CJ | 1 |
| Welch, MJ | 1 |
| Horn, Y | 2 |
| Spigel, L | 1 |
| Marton, LJ | 2 |
| Carvalho, L | 2 |
| Foulkes, K | 2 |
| Mickey, DD | 2 |
| Warrel, RP | 1 |
| Burchenal, JH | 1 |
| Joseph, A | 1 |
| Davenport, C | 1 |
| Kwock, L | 1 |
| Burt, CT | 1 |
| London, RE | 1 |
| Yang, CR | 1 |
| Pliner, L | 1 |
| Russo, P | 1 |
| Schechter, PJ | 1 |
| Levasseur, S | 1 |
| Poleck, T | 1 |
| Burke, G | 1 |
| Shaw, MW | 1 |
| Guinan, PD | 1 |
| McKiel, CF | 1 |
| Dubin, A | 1 |
| Romijn, JC | 1 |
| Verkoelen, CF | 1 |
| Schroeder, FH | 1 |
| Uy, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Placebo-Controlled, Double-Blind Phase IIb Chemoprevention Trial of Difluoromethylornithine in Brothers and First Cousin Males of Familial Prostate Cancer Probands[NCT00006101] | Phase 2 | 76 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Difference refers to absolute difference of 12 months to baseline and % relative difference refers to the ratio of the absolute difference divided by the baseline times 100. (NCT00006101)
Timeframe: Baseline and 12 months
| Intervention | Relative % difference (Mean) | ||
|---|---|---|---|
| Total PSA | Percent Free PSA | Prostate Volume | |
| Eflornithine | -0.75 | 10.21 | 0.94 |
| Placebo | 1.55 | 4.89 | 11.14 |
6 reviews available for eflornithine and Cancer of Prostate
| Article | Year |
|---|---|
[Pharmaco and diet based prostate cancer prevention].
Topics: 5-alpha Reductase Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Diet | 2013 |
Chemoprevention of prostate cancer.
Topics: Androgen Antagonists; Cholesterol; Depression, Chemical; Diet; Eflornithine; Finasteride; Humans; Ma | 1995 |
Chemoprevention of prostate cancer.
Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Dietary Fats; Eflornithine; Fenretinide | 1994 |
Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Antineoplastic Agents; Clinical Trials as Topic; Diet | 1999 |
Chemoprevention in prostate cancer: the role of difluoromethylornithine (DFMO).
Topics: Animals; Eflornithine; Humans; Male; Ornithine Decarboxylase Inhibitors; Polyamines; Prostatic Neopl | 1992 |
Prostatic polyamines and polyamine targeting as a new approach to therapy of prostatic cancer.
Topics: Aziridines; Biological Transport; Cell Division; Dihydrotestosterone; Eflornithine; Guanidines; Huma | 1991 |
9 trials available for eflornithine and Cancer of Prostate
| Article | Year |
|---|---|
Chemoprevention of prostate cancer with the polyamine synthesis inhibitor difluoromethylornithine.
Topics: Biosynthetic Pathways; Chemoprevention; Eflornithine; Enzyme Inhibitors; Humans; Male; Ornithine Dec | 2014 |
The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Eflornithine; Genotype; Humans; Male; | 2008 |
Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine.
Topics: Adult; Carcinoma; Colonic Neoplasms; Eflornithine; Enzyme Induction; Female; Humans; Male; Ornithine | 1993 |
The chemoprevention of prostate cancer and the Prostate Cancer Prevention Trial.
Topics: 5-alpha Reductase Inhibitors; Androgens; Antineoplastic Agents; Chemoprevention; Combined Modality T | 1996 |
Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Biopsy; Breast Neoplasms; Colonic Neoplasms | 1998 |
Low-dose difluoromethylornithine and polyamine levels in human prostate tissue.
Topics: Administration, Oral; Antineoplastic Agents; Eflornithine; Enzyme Inhibitors; Humans; Male; Ornithin | 1999 |
Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Eflornithine; Enzyme Inhibitors; Humans | 2001 |
Urinary polyamine levels in cancer patients treated with D,L-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Eflornithine; Fem | 1989 |
Phase I-II clinical trial with alpha-difluoromethylornithine--an inhibitor of polyamine biosynthesis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Eflornithin | 1987 |
34 other studies available for eflornithine and Cancer of Prostate
| Article | Year |
|---|---|
Polyamine biosynthesis inhibition enhances HSV-1 thymidine kinase/ganciclovir-mediated cytotoxicity in tumor cells.
Topics: Animals; Antiviral Agents; Cell Cycle; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Eflo | 2003 |
Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells.
Topics: Acetyl Coenzyme A; Acetyltransferases; Adenosylmethionine Decarboxylase; Carcinoma; Cell Division; D | 2004 |
Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies.
Topics: Animals; Antineoplastic Agents; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Drug Scree | 2004 |
Karyometry in the early detection and chemoprevention of intraepithelial lesions.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Disease Progression; | 2005 |
Antigrowth effect of some inhibitors of polyamine synthesis on transplantable prostate cancer.
Topics: Animals; Body Weight; Drug Therapy, Combination; Eflornithine; Guanidines; Male; Mitoguazone; Neopla | 1983 |
Potentiation of methylglyoxal-bis-guanylhydrazone by alpha-difluoromethylornithine in rat prostate cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line; Dru | 1984 |
Differential effect of alpha-difluoromethylornithine on the in vivo uptake of 14C-labeled polyamines and methylglyoxal bis(guanylhydrazone) by a rat prostate-derived tumor.
Topics: Animals; Antineoplastic Agents; Biological Transport; Carbon Radioisotopes; Cells, Cultured; Eflorni | 1984 |
Some effects of inhibitors of polyamine synthesis on experimental prostatic cancer.
Topics: Adenine; Adenocarcinoma; Adenosylmethionine Decarboxylase; Animals; Carboxy-Lyases; Eflornithine; Gu | 1984 |
Antigrowth effect of polyamine biosynthesis inhibitors on the Dunning R 3327-G prostatic tumor.
Topics: Adenocarcinoma; Animals; Body Weight; Cell Division; Drug Therapy, Combination; Eflornithine; Guanid | 1984 |
Aminoguanidine reversal of the inhibitory effects of ornithine analogs on the in vitro clonogenic survival of the R3327AT prostate-derived tumor.
Topics: Amine Oxidase (Copper-Containing); Animals; Carboxy-Lyases; Cell Line; Eflornithine; Guanidines; Mal | 1981 |
Copenhagen rat prostatic tumor ornithine decarboxylase activity (ODC) and the effect of the ODC inhibitor alpha-difluoromethylornithine.
Topics: Animals; Antineoplastic Agents; Carboxy-Lyases; Cell Line; Eflornithine; Male; Neoplasms, Experiment | 1982 |
Polyamines and prostatic carcinoma: clinical and therapeutic implications.
Topics: Adult; Aged; Animals; Biomarkers, Tumor; Cell Division; Cell Transformation, Neoplastic; Eflornithin | 1993 |
Genomic methylation patterns of the Dunning R-3327 prostate adenocarcinoma system.
Topics: Adenocarcinoma; Antineoplastic Agents; DNA, Neoplasm; Eflornithine; Humans; Male; Methylation; Prost | 1996 |
In vivo, synergestic inhibition of MAT-LyLu rat prostatic adenocarcinoma growth by polyamine deprivation and low-dose cyclophosphamide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Co | 1996 |
Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
Topics: Adenocarcinoma; Administration, Oral; Animals; Anticarcinogenic Agents; Biomarkers, Tumor; Cell Divi | 2000 |
Novel lysine-spermine conjugate inhibits polyamine transport and inhibits cell growth when given with DFMO.
Topics: Animals; Antineoplastic Agents; Biological Transport; Breast Neoplasms; Cell Division; Eflornithine; | 2000 |
Prostate cancer prevention strategies using antiproliferative or differentiating agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cel | 2001 |
2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Topics: Animals; Anticarcinogenic Agents; Antigens, Polyomavirus Transforming; Apoptosis; Cell Division; Deh | 2001 |
Cytoskeletal organization and cell motility correlates with metastatic potential and state of differentiation in prostate cancer.
Topics: Actins; Adenocarcinoma; Animals; Antineoplastic Agents; Cell Differentiation; Cell Movement; Cytoske | 2001 |
The growth of MAT-LyLu rat prostatic adenocarcinoma can be prevented in vivo by polyamine deprivation.
Topics: Adenocarcinoma; Animals; Diet; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Eflorn | 1991 |
Effect of early and delayed difluoromethylornithine pretreatment upon cyclophosphamide chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Admi | 1990 |
[Therapy with inhibitors of polyamine biosynthesis in refractory prostatic carcinoma. An experimental and clinical study].
Topics: Adenocarcinoma; Adenosylmethionine Decarboxylase; Animals; Antineoplastic Agents; Carboxy-Lyases; Ca | 1985 |
N-3-[18F]fluoropropylputrescine as potential PET imaging agent for prostate and prostate derived tumors.
Topics: Animals; Carbon Radioisotopes; Cell Line; Dihydrotestosterone; Eflornithine; Humans; Male; Prostate; | 1989 |
Effect of DMSO and DFMO on rat prostate tumor growth.
Topics: Adenocarcinoma; Animals; Dimethyl Sulfoxide; Disease Models, Animal; Eflornithine; Male; Neoplasm Tr | 1989 |
Conventional chemotherapeutic agents combined with DMSO or DFMO in treatment of rat prostate carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophos | 1989 |
alpha-Difluoromethylornithine enhancement of 14C-putrescine uptake by an androgen-dependent prostatic tumor.
Topics: Adenocarcinoma; Androgens; Animals; Carbon Radioisotopes; Dexamethasone; Dihydrotestosterone; Eflorn | 1986 |
Phase I trial of alpha-difluoromethyl ornithine (DFMO) and methylglyoxal bis (guanylhydrazone) (MGBG) in patients with advanced prostatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Dr | 1986 |
Fluorine-19 NMR studies of tumor-bearing rats treated with difluoromethylornithine.
Topics: Adenocarcinoma; Animals; Eflornithine; Fluorine; Magnetic Resonance Spectroscopy; Male; Prostatic Ne | 1987 |
Cytotoxic activity of a polyamine analogue, monoaziridinylputrescine, against the PC-3 human prostatic carcinoma cell line.
Topics: Cell Line; Cell Survival; Eflornithine; Humans; Kinetics; Male; Mathematics; Prostatic Neoplasms; Pu | 1987 |
The effects of polyamine antimetabolites on polyamine-responsive casein kinase activity.
Topics: Adenocarcinoma; Adenosylmethionine Decarboxylase; Alkynes; Animals; Antineoplastic Agents; Casein Ki | 1987 |
Combination therapy using polyamine synthesis inhibitor alpha-difluoromethylornithine and adriamycin in treatment of rats carrying the Dunning R3327 MAT-LyLu prostatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Doxorubicin; Efl | 1987 |
Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects.
Topics: Androgens; Cell Count; Cell Division; Coloring Agents; Drug Screening Assays, Antitumor; Eflornithin | 1988 |
Cytotoxic activity of aziridinyl putrescine enhanced by polyamine depletion with alpha-difluoromethylornithine.
Topics: Antineoplastic Agents; Cell Line; Eflornithine; Humans; Male; Ornithine; Polyamines; Prostatic Neopl | 1985 |
[Polyamines, polyamine antimetabolites and urogenital tumors. State of research and clinical results].
Topics: Adenosylmethionine Decarboxylase; Antimetabolites, Antineoplastic; Carboxy-Lyases; Drug Combinations | 1985 |